Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma
Status:
Completed
Trial end date:
2004-06-01
Target enrollment:
Participant gender:
Summary
The primary objectives of the study are to evaluate the safety and the efficacy in patients
with malignant lymphoma or acute leukemia who are repeatedly administered for SR29142 5 days
in two dosage groups.
Secondary objectives are to determine the pharmacokinetic (PK) parameters of SR29142 , to
assess anti-SR29142 antibody production in patients with malignant lymphoma and acute
leukemia, and to estimate the optimal dosage of SR29142 for Japanese patients from the
results of efficacy and safety evaluations.